A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.
Rachel A. Freedman
Research Funding - Eisai; Puma Biotechnology
Ines Maria Vaz Duarte Luis
No relevant relationships to disclose
William Thomas Barry
No relevant relationships to disclose
Ian E. Krop
Consultant or Advisory Role - Roche/Genentech (U)
Research Funding - Roche/Genentech
Nikhil Wagle
No relevant relationships to disclose
Alarice Lowe
No relevant relationships to disclose
Sarah Galler
No relevant relationships to disclose
Jessica Sohl
No relevant relationships to disclose
Steven J. Isakoff
No relevant relationships to disclose
Nadine M. Tung
No relevant relationships to disclose
Eric P. Winer
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Nancy U. Lin
Research Funding - Array BioPharma; Genentech; GlaxoSmithKline